The first half of 2025 has been volatile for stocks, making it crucial to find the right companies for your portfolio. Consider your stock preferences, industries of interest, capital available, and risk tolerance. Hims & Hers Health (NYSE: HIMS) saw a 200% stock surge in the last year, focusing on healthcare and personalized treatments.

However, Hims & Hers faces challenges as the FDA resolved drug shortages, impacting its weight loss offerings. The company is shifting to other areas like sexual health, dermatology, and mental health. An acquisition of Zava expands its reach in Europe, hinting at growth beyond weight loss services. Revenue grew by 110% in Q1.

Doximity (NYSE: DOCS) has seen a 100% share increase over a year, serving as a digital platform for medical professionals. Its services include newsfeeds, job searches, telehealth solutions, and advertising opportunities for pharmaceutical companies. In fiscal 2025, revenue spiked 20% to $570.4 million, showcasing profitability and potential for investors.

Doximity’s revenue growth comes from advertising and selling information to healthcare entities. Its free platform for medical professionals offers tools like Doximity Dialer and AI-powered note-taking. The company reported net income of $223.2 million, up 51% year over year. Investors are eyeing this healthcare stock with advertising at its core.

For investors seeking growth, the Motley Fool’s expert analyst team has unveiled the 10 best stocks to buy now, potentially including Hims & Hers Health. Stock Advisor’s total average return beats the S&P by 841.12%, highlighting the potential for significant returns. Don’t miss out on the latest top 10 list and investment opportunities.

Read more at Yahoo Finance: 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run